Advanced Cell Diagnostics has entered into an agreement with Johns Hopkins University on behalf of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, whereby ACD’s RNAscope technology will be used to validate novel biomarkers and drug targets for cancer immunotherapy.
Cancer immunotherapy has been gaining momentum, with the FDA approval of anti-CTLA-4 therapy for melanoma and with the recent durable remissions produced by targeting PD1 in multiple solid tumors in early-phase clinical trials led by Johns Hopkins investigators. With many additional immune modulatory molecules identified for targeting that play chief roles in specific subsets of cancer, it will be critical to develop standardized biomarkers to guide the application of immune therapies on a patient-by-patient basis.
RNAscope is an automated multiplex RNA in situ hybridization platform that detects and quantifies biomarkers with single-molecule sensitivity. The platform provides single-cell gene-expression information within the context of intact tissue, enabling molecular and histopathological analysis on a platform compatible with routine clinical specimens and standard clinical laboratory workflow. RNAscope assays can be developed and validated in two weeks for virtually any gene in any genome. ACD offers RNAscope-based products and services worldwide to scientists in a range of areas, from basic research to companion diagnostics for personalized medicine.
Advanced Cell Diagnostics, 510-576-8800